Mendus AB (Sweden) Performance
| IMMU Stock | SEK 7.25 0.30 3.97% |
The company secures a Beta (Market Risk) of -0.0916, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Mendus AB are expected to decrease at a much lower rate. During the bear market, Mendus AB is likely to outperform the market. At this point, Mendus AB has a negative expected return of -0.51%. Please make sure to verify Mendus AB's maximum drawdown, potential upside, and the relationship between the treynor ratio and value at risk , to decide if Mendus AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mendus AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 167.6 M | |
| Total Cashflows From Investing Activities | -1.4 M |
Mendus |
Mendus AB Relative Risk vs. Return Landscape
If you would invest 1,016 in Mendus AB on November 2, 2024 and sell it today you would lose (291.00) from holding Mendus AB or give up 28.64% of portfolio value over 90 days. Mendus AB is generating negative expected returns and assumes 3.3648% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Mendus, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Mendus AB Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mendus AB's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mendus AB, and traders can use it to determine the average amount a Mendus AB's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1528
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMMU |
Estimated Market Risk
| 3.36 actual daily | 29 71% of assets are more volatile |
Expected Return
| -0.51 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mendus AB is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mendus AB by adding Mendus AB to a well-diversified portfolio.
Mendus AB Fundamentals Growth
Mendus Stock prices reflect investors' perceptions of the future prospects and financial health of Mendus AB, and Mendus AB fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mendus Stock performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (69.15) % | |||
| Current Valuation | 607.17 M | |||
| Shares Outstanding | 199.4 M | |||
| Price To Earning | (4.53) X | |||
| Price To Book | 1.13 X | |||
| Price To Sales | 354.29 X | |||
| EBITDA | (128.28 M) | |||
| Cash And Equivalents | 155.31 M | |||
| Cash Per Share | 3.94 X | |||
| Debt To Equity | 0.20 % | |||
| Book Value Per Share | 2.81 X | |||
| Cash Flow From Operations | (138.03 M) | |||
| Earnings Per Share | (0.63) X | |||
| Total Asset | 720.98 M | |||
| Retained Earnings | (100 M) | |||
| Current Asset | 45 M | |||
| Current Liabilities | 9 M | |||
About Mendus AB Performance
Assessing Mendus AB's fundamental ratios provides investors with valuable insights into Mendus AB's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mendus AB is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer and Phase IbII clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase III clinical trials to treat liver cancer and gastrointestinal stromal tumors. Immunicum AB has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase IbII study. Immunicum is traded on Stockholm Stock Exchange in Sweden.Things to note about Mendus AB performance evaluation
Checking the ongoing alerts about Mendus AB for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mendus AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mendus AB generated a negative expected return over the last 90 days | |
| Mendus AB has high historical volatility and very poor performance | |
| Net Loss for the year was (130.1 M) with profit before overhead, payroll, taxes, and interest of 6 K. | |
| Mendus AB has accumulated about 155.31 M in cash with (138.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.94. | |
| Roughly 58.0% of the company shares are held by company insiders |
- Analyzing Mendus AB's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mendus AB's stock is overvalued or undervalued compared to its peers.
- Examining Mendus AB's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mendus AB's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mendus AB's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mendus AB's stock. These opinions can provide insight into Mendus AB's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mendus Stock Analysis
When running Mendus AB's price analysis, check to measure Mendus AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mendus AB is operating at the current time. Most of Mendus AB's value examination focuses on studying past and present price action to predict the probability of Mendus AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mendus AB's price. Additionally, you may evaluate how the addition of Mendus AB to your portfolios can decrease your overall portfolio volatility.